The reproductive tech company Orchid recently launched a genetic test that promises a whole genome sequencing report for embryos. It is the first such test commercially available to couples undergoing in vitro fertilization (IVF) and claims to detect things like congenital disabilities, neurodevelopmental disorders, chromosomal abnormalities, and even future cancers. The company has been…
This post has been syndicated from Truthout, where it was published under this address.